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Purpose of the study
To compare the efficacy and safety of switching from lopi-
navir/r (LPV/r) to atazanavir/r (ATV/r) in suppressed
patients vs. continuing a LPV/r HAART at 2 years.
Methods
Randomized, open-label 96-week trial including patients
with virological suppression (<200 copies/ml; >= 6
months) on a LPV/r-containing HAART. Patients were
randomized 1:1 to either continue LPV/r or switch to ATV/
r. Patients with >4 PI-associated mutations and/or failed
to >2 PI-containing regimens were excluded. Primary end-
point: proportion of patients with treatment failure (ITT
switching = failure) at 48 weeks. Virologic failure: two
consecutive viral load >200 copies/ml (OT).
Summary of results
248 patients were assigned to continue LPV/r (n = 127) or
to switch to ATV/r (n = 121). Baseline characteristics were
balanced, including age, sex, risk for HIV infection, liver
enzymes, fasting lipid profile, time on prior ARV, previous
exposure to PI-containing regimens, and median CD4
(around 450 cells/mm3). 30% had available evidence of
harboring one or more PI-associated mutations (with
10% showing at least one major mutation, IAS defini-
tion). Treatment failure occurred in 30% (40/127) in the
LPV/r arm and in 25% (33/121) in the ATV/r arm (differ-
ence -4.2%; 95% CI from -15.6% to 7.1%). Virological
failure occurred in 9% (12/127) in the LPV/r arm and in
8% (11/121) in the ATV/r arm (difference -0.36%; 95% CI
from -7.6 to 6.9%). Median CD4 changes from baseline
were 100.5 and 40 cells/mm3 in the LPV/r and ATV/r arm,
respectively. Adverse events leading to study drug discon-
tinuation occurred in 6% in the LPV/r arm and 5% in the
ATV/r arm. Fasting TG and total cholesterol decreased sig-
nificantly in the ATV/r arm, -53 and -24 mg/dL, respec-
tively. Changes in ALT/AST were similar in both arms and
significant total bilirubin elevations were frequently seen
in the ATV/r arm.
Conclusion
Switching to ATV/r in virologically suppressed patients
who were receiving a LPV/r-containing HAART provided
comparable and durable efficacy with improved lipid
parameters.
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